Skip to main content
. Author manuscript; available in PMC: 2021 Nov 8.
Published in final edited form as: Diabetes Obes Metab. 2020 Dec 2;23(2):480–488. doi: 10.1111/dom.14241

TABLE 1.

Clinical characteristics on admission and glycaemic control

Variable Placebo Sitagliptin P-value
Number of participants 91 91
Gender .24
 Male 70 (77) 63 (69)
 Female 21 (23) 18 (31)
Age, years 64 ± 9 63 ± 8 .48
Race .92
 Caucasian 68 (75) 67 (74)
 African American 19 (21) 21 (23)
 Other 4(4) 3(3)
Body weight, kg 97 ± 21 96 ± 19 .96
BMI, kg/m2 32 ± 7 32 ± 6 .34
Diabetes history
 Diabetes duration, years 9±7 12 ± 10 .18
 Outpatient diabetes therapy .32
 None 7 (8) 2 (2)
 Diet only 5 (5) 3 (3)
 OAD only 52 (57) 63 (69)
 DPP-4 inhibitors 11 (17) 20 (27)
 Metformin 62 (89) 66 (81)
 Sulphonylureas 18 (28) 24 (32)
 Thiazolinediones 0(0) 6 (8)
 SGLT-2 7 (14) 5 (8)
 OAD + insulin 17 (19) 15 (16)
 GLP-1 0 (0) 2 (2)
 GLP-1 + OAD 2 (2) 2 (2)
 Insulin only 7 (8) 3 (3)
Home total insulin dose, units 50.3 ± 34.4 57.1 ± 50.4 .95
Total insulin dose adjusted by weight 0.49 ± 0.33 0.61 ± 0.51 .37
Type of surgery .54
 Elective/outpatient 53 (59) 49 (54)
 Emergent 5(6) 10 (11)
 Transfer from another hospital 7(8) 5 (5)
 Urgent 25 (28) 27 (30)
Type of CABG procedure .65
 Open CABG 76 (84) 79 (87)
 Robotic CABG 14 (16) 12 (13)
 Length of surgery (minutes) 311 ± 90 310 ± 93 .85
 Number of vessels, median (Q1, Q3) 3.0 [2.0, 4.0] 3.0 [2.0,3.0] .89
ASA .83
 III 12 (13) 14 (15)
 IV 77 (86) 77 (85)
 V 1(1) 0 (0)

Abbreviations: ASA, American Society of Anaesthesiology; BMI, body mass index; CABG, coronary artery bypass graft surgery; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; ICU, intensive care unit; OAD, oral antidiabetic drug; SGLT-2, sodium-glucose co-transporter-2.

Data are n (%), mean ± standard deviation, or median [IQR]; IQR, interquartile range.